MedTrace Logo

Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy

NCT00630149 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2012-02-16

No results posted yet for this study

Summary

This is a pilot phase II study of locally advanced or metastatic nasopharyngeal carcinoma (NPC) with the single drug Alimta. The objective of this study is to assess efficacy and safety profiles of Alimta as 2nd line treatment for patients with advanced NPC.

Conditions

  • Nasopharyngeal Neoplasms

Interventions

DRUG

Pemetrexed (Alimta)

500 mg/m2 in Cycle 1, every 3 weeks, with folic acid and vitamin B12 supplementation.

Sponsors & Collaborators

Principal Investigators

  • Li Zhang, Master · Cancer Center of Sun-Yat Sen University (CCSYSU)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2011-11-30
Completion
2012-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00630149 on ClinicalTrials.gov